Business
PRTC Presents Data for LYT-210 IO Program at AACR
PRTC Presents Data for LYT-210 IO Program at AACR.
About this update from Puretech Health Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 0542V\n PureTech Health PLC\n 12 April 2021\n \n \n \n \n 12 April 2021\n \n \n PureTech Health plc\n \n \n \n \n \n PureTech Presents Promising Preclinical Data from LYT-210 Immuno-Oncology Program at American Association for Cancer Research (AACR) Annual Meeting\n \n \n \n \n \n Novel antibody demonstrates highly specific and highly potent targeting of immunosuppressive γ1 T cells from cancer patients\n \n \n \n \n \n Enriched in many intractable solid tumors and blood of cancer patients, γ1 T cells represent important new target for cancer immunotherapy \n \n \n \n \n \n \n \n PureTech Health plc\n \n \n (Nasdaq: PRTC, LSE: PRTC) (\"PureTech\" or the \"Company\"), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, today announced the presentation of a scientific poster detailing additional promising preclinical results for its LYT-210 antibody at the 2021 American Association for Cancer Research (AACR) Annual Virtual Meeting.\n \n \n \n \n \n LYT-210 is a novel, fully human monoclonal antibody (mAb) directed against T cells bearing γ1 receptors, which are known to suppress the anti-tumor immune response. The new research shared at AACR demonstrates that LYT-210 is both highly specific and highly potent, rapidly inducing cell death of immune-suppressive γ1 T cells, while sparing other T cells that play important roles in a healthy immune response. The research was conducted in vitro using both patient blood and cancer tissue. LYT-210 has potential as either a single agent or in combination with checkpoint inhibitors and other anti-cancer treatments.\n \n \n \n \n \n \"The role of γ1 T cells in cancer immune suppression has come into sharp focus in recent years. We now know that these cells deploy multiple immunosuppressive signals to dampen the anti-tumor response and enable the cancer to grow and spread,\" said \n Aleksandra Filipovic\n , M.D. Ph.D., Head of Oncology\n at PureTech. \"We are excited by these new data demonstrating that our LYT-210 therapeutic candidate can precisely target and swiftly deplete pathogenic γ1 T cells. We believe that removing these culprits from the tumor microenvironment systemically may have the \n potential to reawaken...